Single centre ,Phase IV , interventional, The study includes :~* 200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients will have placebo .~The patients will be randomized to the active product (arm 1) or to placebo (arm 2).~The study consists of 4 visits as the following :~Visit 1 : on day 1 to check patient eligibility and also for randomization .~Visit 2 : on day 4 to assess target parameters~Visit 3 : on day 8 to assess target parameters~Visit 4 : on day 16 to assess target parameters~Study objective :Assessment the Efficacy of Topical r-Hirudin in treatment of haematomas ,also in resolving of the associated oedema~Study duration : 6 months~Selection of trial subjects:~Inclusion Criteria :~Age of patients between 20 and 60 years old.~Patients with all types of haematomas.~Exclusion Criteria:~Presence of infected wound requiring hospitalization or surgical intervention.~History of allergy or hypersensitivity to any of the ingredients.~Patients with coagulation disorders like haemophilia.~Patients who are on anticoagulants like Warfarin and Acetylsalicylic acid .~Patients who are taking digestive enzymes like alfa chemotrypsin.~Target parameters :~1.Size of haematoma.( Measured by ruler) , The ruler will measure the longest 2 intersecting line.~2.Size of oedema : by measurement of oedema circumference~3.Pain (by Vas score).~4.Change in colour ( by colour grade scale ) .
Single centre ,Phase IV , interventional, The study includes :~200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients will have placebo .~The patients will be randomized to the active product (arm 1) or to placebo (arm 2).~The study consists of 4 visits as the following :~Visit 1 : on day 1 to check patient eligibility and also for randomization .~Visit 2 : on day 4 to assess target parameters~Visit 3 : on day 8 to assess target parameters~Visit 4 : on day 16 to assess target parameters